Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Brilliant Green. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.69 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.97 |
| ▸ | MEN1 | O00255 | 6/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.97 |
| ▸ | HPGD | P15428 | 5/20 | 0.97 |
| ▸ | THRB | P10828 | 4/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.97 |
| ▸ | TP53 | P04637 | 3/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.97 |
| ▸ | HTT | P42858 | 3/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.97 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.97 |
| ▸ | RECQL | P46063 | 2/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brilliant Green SCHEMBL29365780 | 0.99 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2ATDP1HPGD | |
| Brilliant Green SCHEMBL28515271 | 0.96 | MEN1 (0.90) | ALDH1A1MEN1KMT2ATDP1HPGD | |
| Brilliant Green SCHEMBL29379377 | 0.93 | MEN1 (0.85) | ALDH1A1MEN1KMT2ATDP1HPGD | |
| Brilliant Green SCHEMBL171205 | 0.90 | TDP1 (0.84) | ALDH1A1MEN1KMT2ATDP1HPGD | |
| Brilliant Green SCHEMBL28216 | 0.89 | TDP1 (0.88) | ALDH1A1MEN1KMT2ATDP1HPGD | |
| SCHEMBL171207 | 0.85 | TDP1 (0.79) | ALDH1A1MEN1KMT2ATDP1HPGD | |
| Hexamethyl Pararosaniline SCHEMBL94116 | 0.84 | TDP1 (0.96) | ALDH1A1MEN1KMT2ATDP1HPGD | |
| Iodide SCHEMBL31635600 | 0.83 | TDP1 (0.77) | ALDH1A1MEN1KMT2ATDP1HPGD | |
| Hydrochloric Acid SCHEMBL2053249 | 0.83 | TDP1 (0.82) | ALDH1A1MEN1KMT2ATDP1HPGD | |
| Hexamethyl Pararosaniline SCHEMBL9171 | 0.83 | TDP1 (1.00) | ALDH1A1MEN1KMT2ATDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326754-A1 | DNA-PK Inhibitor Compounds and Uses Thereof | ADMARE THERAPEUTICS SOC (CA) | 2025-10-23 | — | — | US | disclosed |
| EP-4611606-A1 | METHODS AND DEVICES FOR MULTIPHOTON IMAGING AND LASER-TISSUE INTERACTIONS | The Regents of University of California (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3965738-B1 | METHOD FOR PRODUCTION OF LIPOSOMES | UNIV DO MINHO (PT) | 2025-08-06 | — | — | EP | disclosed |
| EP-4522620-A1 | DNA-PK INHIBITOR COMPOUNDS AND USES THEREOF | Admare Therapeutics Society (CA) | 2025-03-19 | — | — | EP | disclosed |
| US-20240246960-A1 | 7-Morpholino-L,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2024-07-25 | — | — | US | disclosed |
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | LIFEARC (GB) | 2024-07-18 | — | — | US | disclosed |
| WO-2024124139-A1 | METHODS AND DEVICES FOR MULTIPHOTON IMAGING AND LASER-TISSUE INTERACTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-4305032-A1 | 7-MORPHOLINO-1,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR | Admare Therapeutics Society (CA) | 2024-01-17 | — | — | EP | disclosed |
| EP-4305031-A1 | 7-MORPHOLINO-L,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR | Admare Therapeutics Society (CA) | 2024-01-17 | — | — | EP | disclosed |
| CN-111821982-B | Graphene oxide-cerium oxide-ferric oxide composite material, synthetic method and application thereof in catalytic degradability | 闽南师范大学 | 2024-01-12 | — | — | CN | disclosed |
| WO-2023215991-A1 | DNA-PK INHIBITOR COMPOUNDS AND USES THEREOF | adMare Therapeutics Society (CA) | 2023-11-16 | — | — | WO | disclosed |
| CN-111569890-B | Graphene oxide-terbium oxide-ferric oxide composite material, synthetic method and application thereof in catalytic degradation | 闽南师范大学 | 2023-09-26 | — | — | CN | disclosed |
| CN-109983404-B | Transfer film, electrode protection film, laminate, capacitive input device, and method for manufacturing touch panel | 富士胶片株式会社 | 2022-10-28 | — | — | CN | disclosed |
| WO-2022187964-A1 | 7-MORPHOLINO-L,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR | adMare Therapeutics Society (CA) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022187965-A1 | 7-MORPHOLINO-1,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR | adMare Therapeutics Society (CA) | 2022-09-15 | — | — | WO | disclosed |
| US-20220241203-A1 | METHOD FOR PRODUCTION OF LIPOSOMES | UNIVERSIDADE DO MINHO (PT) | 2022-08-04 | — | — | US | disclosed |
| EP-3792825-B1 | METHODS AND SYSTEMS FOR ASSESSING HISTOLOGICAL STAINS | ABBOTT LAB (US) | 2022-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | DCK, ERCC2, POLK | SLC6A4 4437/4885OPRM1 3658/4885ALDH1A1 2208/4885 |
| US-20240246960-A1 | 7-Morpholino-L,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | DCK, ERCC2, POLK | SLC6A4 4360/4885OPRM1 3818/4885ALDH1A1 2452/4885 |
| US-20250326754-A1 | DNA-PK Inhibitor Compounds and Uses Thereof | DCK, CHEK1, CHEK2 | SLC6A4 4239/4885OPRM1 4285/4885ALDH1A1 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.